Evidence map›Paper›PMID 25966620›Full record

ArticleJournal of vascular research2015

Glucagon-Like Peptide-1 Receptor Activation Does not Affect Re-Endothelialization but Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Nondiabetic Model of Arterial Injury.

Linnea Eriksson, Robert Saxelin, Samuel Röhl, Joy Roy, Kenneth Caidahl, Thomas Nyström, Ulf Hedin, Anton Razuvaev

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Journal of vascular research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02621489. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02621489 phase4completed

Effects on Re-endothelialisation With Bydureon Treatment Add on to Insulin Versus Insulin Alone, Both in Combination With Metformin in Type 2 Diabetic Subjects

Ran2015Enrolled38Registered outcomes16Posted comparisons0ConditionsAtherosclerosis, Diabetes, RestenosisArmsBydureon, Humulin kwickpen, Metformin
Open the trial in the graph
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Linnea ErikssonDepartment of Clinical Science and Education, Södersjukhuset, Stockholm, Sweden.
Robert Saxelin
Samuel Röhl
Joy Roy
Kenneth Caidahl
Thomas Nyström
Ulf Hedin
Anton Razuvaev
Stockholm South General Hospital · SEKarolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledDiabetic patients have an increased risk of restenosis and late stent thrombosis after angioplasty, i.e. complications that are related to a defective re-endothelialization. Exendin-4, a stable glucagon-like peptide (GLP)-1 receptor agonist, has been suggested to influence the formation of intimal hyperplasia and to increase endothelial cell proliferation in vitro. Thus, the aim of this study was to investigate the mechanisms by which treatment with exendin-4 could influence re-endothelialization and intimal hyperplasia after vascular injury.

methodsSprague-Dawley rats were subjected to balloon injury of the left common carotid artery and treated for 4 weeks with exendin-4 or vehicle. Intimal hyperplasia and vessel wall elasticity were monitored noninvasively by high-frequency ultrasound, and re-endothelialization was evaluated upon sacrifice using Evans blue dye. RESULTS AND

conclusionExendin-4 selectively reduced the proliferation of smooth muscle cells (SMCs) and intimal hyperplasia in vivo without affecting the re-endothelialization process, but treatment with exendin-4 improved arterial wall elasticity. Our data also show that exendin-4 significantly decreased the proliferation and increased the apoptosis of SMCs in vitro, effects that appear to be mediated through cAMP signaling and endothelial nitric oxide synthase following GLP-1 receptor activation. Together, these effects of exendin-4 are highly desirable and may lead to an improved outcome for patients undergoing vascular interventions.

Indexed as

AnimalsBlood GlucoseCarotid Artery, CommonCarotid Artery InjuriesCell DivisionCells, CulturedCyclic AMPDisease Models, AnimalEndothelium, VascularExenatideFatty Acids, NonesterifiedGlucagon-Like Peptide-1 ReceptorHyperplasiaInsulinMaleMyocytes, Smooth MuscleBlood GlucoseCyclic AMPExenatideFatty Acids, NonesterifiedGlp1r protein, ratGlucagon-Like Peptide-1 ReceptorInsulinNitric Oxide Synthase Type IIINos3 protein, ratPeptidesReceptors, GlucagonVenoms

Identifiers

PMID25966620
OpenAlexW1483874092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.